apyrase and Neoplasms

apyrase has been researched along with Neoplasms* in 36 studies

Reviews

16 review(s) available for apyrase and Neoplasms

ArticleYear
CD39 - A bright target for cancer immunotherapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 151

    The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumor microenvironment, and cancer immune evasion largely involves the generation of high amounts of immunosuppressive extracellular adenosine (eADO). Consequently, inhibition of eADO-generating enzymes and/or eADO receptors can effectively restore the antitumor immunity of multiple immune cells. With several clinical strategies currently being explored to modulating the eADO pathway in patients with cancer, recent clinical data with antagonists targeting CD73 and A

    Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Apyrase; Humans; Immunotherapy; Neoplasms; Tumor Microenvironment

2022
Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Human immunology, 2021, Volume: 82, Issue:4

    Immunosuppressive activity of regulatory T cells (Tregs) is one of the mechanisms promoting carcinogenesis. Intratumoral Tregs have some phenotypic and functional traits that lower the efficiency of antitumor immune response, which makes them a good target for immunotherapy. Several approaches to cancer immunotherapy are being developed along this vector: deletion of tumor-infiltrating Tregs, inhibition of their homing to the tumor microenvironment, and functional downregulation of Tregs. Studies of the past decade have demonstrated the role of Tregs and ectonucleotidases CD39 and CD73 in the generation of immunosuppressive extracellular adenosine. Pharmacological targeting of CD39 and CD73 can restrain the activity of suppressor cells and promote the efficiency of cancer therapy. Here we review the latest data on issues regarding the role of extracellular adenosine and its receptors in antitumor immune response, adenosine generation mechanisms involving Tregs and the membrane proteins CD39 and CD73. Innovative approaches to antitumor immunotherapy and clinical studies of Treg targeting and application of anti-CD39/CD73 antibodies, adenosine receptor antagonists, and small-molecule inhibitors of ectonucleotidase activity are explored.

    Topics: 5'-Nucleotidase; Adenosine; Animals; Antigens, CD; Antineoplastic Agents; Apyrase; Forkhead Transcription Factors; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; T-Lymphocytes, Regulatory; Tumor Microenvironment

2021
Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
    Life sciences, 2021, Oct-01, Volume: 282

    The immunosuppressive tumor microenvironment has been implicated in attenuating anti-tumoral immune responses and tumor growth in various cancers. Inhibitory immune checkpoints have been introduced as the primary culprits for developing the immunosuppressive tumor microenvironment. Therefore, a better understanding of the cross-talk between inhibitory immune checkpoints in the tumor microenvironment can pave the way for introducing novel approaches for treating affected patients. Growing evidence indicates that CD39 and CD73, as novel checkpoints, can transform adenosine triphosphate (ATP)-mediated pro-inflammatory tumor microenvironment into an adenosine-mediated immunosuppressive one via the purinergic signaling pathway. Indeed, enzymatic processes of CD39 and CD73 have crucial roles in adjusting the extent, intensity, and chemical properties of purinergic signals. This study aims to review the biological function of CD39 and CD73 and shed light on their significance in regulating anti-tumoral immune responses in various cancers.

    Topics: 5'-Nucleotidase; Apyrase; GPI-Linked Proteins; Humans; Immune Tolerance; Neoplasm Proteins; Neoplasms; Signal Transduction; Tumor Microenvironment

2021
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.
    Clinical and experimental immunology, 2020, Volume: 200, Issue:2

    Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and predict clinical responses. Recently, a key role has been assigned to innate immune mechanisms in checkpoint blockade-driven anti-tumor responses. However, inflammatory pathways can both improve and impair anti-tumor immunity. In this review, we discuss how different inflammatory pathways, particularly inflammasome activation, can influence the clinical outcome of immune checkpoint blockers. Inflammasome activation may reinforce anti-tumor immunity by boosting CD8

    Topics: Animals; Antineoplastic Agents, Immunological; Apyrase; CD8-Positive T-Lymphocytes; Humans; Inflammasomes; Membrane Proteins; Neoplasm Proteins; Neoplasms; Th17 Cells

2020
Targeting CD39 in cancer.
    Nature reviews. Immunology, 2020, Volume: 20, Issue:12

    The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer; in particular, recent clinical data with CD73 antagonists and inhibitors of A

    Topics: Animals; Antigens, CD; Apyrase; Humans; Immunity; Immunomodulation; Immunotherapy; Neoplasms; Signal Transduction

2020
Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.
    Current opinion in pharmacology, 2020, Volume: 53

    The promising results of the first in-human clinical study using A2AR antagonists for treatment of renal cell carcinoma highlight two decades of research into the hypoxia-A2-adenosinergic pathway. Importantly, clinical responses have been observed in patients who previously progressed on anti-PD-1/PDL-1 therapy, emphasizing the clinical importance of targeting A2AR signaling in cancer immunotherapies. Recently, it has been shown that systemic oxygenation weakens all known stages of the hypoxia-A2-adenosinergic axis. Therefore, we advocate the clinical use of systemic oxygenation and oxygenation agents in combination with A2AR blockade to further improve cancer immunotherapies. This approach is expected to completely eliminate the upstream (hypoxia-HIF-1α) and downstream (adenosine-A2AR) stages of the immunosuppressive hypoxia-adenosinergic signaling axis. This might be a necessary strategy to maximize the therapeutic benefits of A2AR antagonists and increase susceptibility of tumors to cancer treatments.

    Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antigens, CD; Apyrase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immune Tolerance; Immunotherapy; Neoplasms; Oxygen; Receptor, Adenosine A2A; Tumor Hypoxia

2020
Targeting the adenosine pathway for cancer immunotherapy.
    Seminars in immunology, 2019, Volume: 42

    Suppression of anti-tumor immunity is recognized as a critical step in the development of many types of cancers. Over the past decade, a multitude of immunosuppressive pathways occurring in the tumor microenvironment (TME) have been identified. Amongst them, the hydrolysis of extracellular ATP into adenosine by ecto-nucleotidases has been increasingly documented as new immune checkpoint pathway that can significantly impair anti-tumor immunity of multiple types of cancer. In this review, we summarize past and recent research on the ecto-nucleotidases CD39 and CD73, conducted by our group and others, that recently lead to the development and clinical testing of adenosine targeting agents for cancer immunotherapy.

    Topics: 5'-Nucleotidase; Adenosine; Animals; Antigens, CD; Apyrase; Humans; Immunotherapy; Neoplasms; Signal Transduction

2019
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
    Journal of cellular physiology, 2018, Volume: 233, Issue:3

    Tumor cells overcome anti-tumor responses in part through immunosuppressive mechanisms. There are several immune modulatory mechanisms. Among them, adenosine is an important factor which is generated by both cancer and immune cells in tumor microenvironment to suppress anti-tumor responses. Two cell surface expressed molecules including CD73 and CD39 catalyze the generation of adenosine from adenosine triphosphate (ATP). The generation of adenosine can be enhanced under metabolic stress like tumor hypoxic conditions. Adenosine exerts its immune regulatory functions through four different adenosine receptors (ARs) including A1, A2A, A2B, and A3 which are expressed on various immune cells. Several studies have indicated the overexpression of adenosine generating enzymes and ARs in various cancers which was correlated with tumor progression. Since the signaling of ARs enhances tumor progression, their manipulation can be promising therapeutic approach in cancer therapy. Accordingly, several agonists and antagonists against ARs have been designed for cancer therapy. In this review, we will try to clarify the role of different ARs in the immunopathogenesis, as well as their role in the treatment of cancer.

    Topics: 5'-Nucleotidase; Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; GPI-Linked Proteins; Humans; Mice; Neoplasms; Receptor, Adenosine A1; Receptor, Adenosine A3; Receptors, Adenosine A2; Signal Transduction; Tumor Escape

2018
Targeting A2 adenosine receptors in cancer.
    Immunology and cell biology, 2017, Volume: 95, Issue:4

    Tumor cells use various ways to evade anti-tumor immune responses. Adenosine, a potent immunosuppressive metabolite, is often found elevated in the extracellular tumor microenvironment. Therefore, targeting adenosine-generating enzymes (CD39 and CD73) or adenosine receptors has emerged as a novel means to stimulate anti-tumor immunity. In particular, the A2 (A2a and A2b) adenosine receptors exhibit similar immunosuppressive and pro-angiogenic functions, yet have distinct biological roles in cancer. In this review, we describe the common and distinct biological consequences of A2a and A2b adenosine receptor signaling in cancer. We discuss recent pre-clinical studies and summarize the different mechanisms-of-action of adenosine-targeting drugs. We also review the rationale for combining inhibitors of the adenosine pathway with other anticancer therapies such immune checkpoint inhibitors, tumor vaccines, chemotherapy and adoptive T cell therapy.

    Topics: 5'-Nucleotidase; Adenosine A2 Receptor Antagonists; Animals; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Apyrase; Cancer Vaccines; Combined Modality Therapy; Costimulatory and Inhibitory T-Cell Receptors; Humans; Immunity; Immunotherapy, Adoptive; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Receptors, Adenosine A2; Tumor Microenvironment

2017
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
    Immunological reviews, 2017, Volume: 276, Issue:1

    Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign. This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state. Immunotherapies are newly developing interventions that modify the patient's immune system to fight cancer, by either directly stimulating rejection-type processes or blocking suppressive pathways. Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized "immune checkpoint mediator" that interferes with anti-tumor immune responses. In this review, we focus on CD39 and CD73 ectoenzymes and encompass aspects of the biochemistry of these molecules as well as detailing the distribution and function on immune cells. Effects of CD39 and CD73 inhibition in preclinical and clinical studies are discussed. Finally, we provide insights into potential clinical application of adenosinergic and other purinergic-targeting therapies and forecast how these might develop in combination with other anti-cancer modalities.

    Topics: 5'-Nucleotidase; Animals; Antibodies, Monoclonal; Antigens, CD; Apyrase; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; GPI-Linked Proteins; Humans; Immunotherapy; Neoplasms; Tumor Escape; Tumor Microenvironment

2017
Regulation of the T Cell Response by CD39.
    Trends in immunology, 2016, Volume: 37, Issue:7

    The ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, or CD39) catalyzes the phosphohydrolysis of extracellular ATP (eATP) and ADP (eADP) released under conditions of inflammatory stress and cell injury. CD39 generates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine. These ectonucleotidases have a major impact on the dynamic equilibrium of proinflammatory eATP and ADP nucleotides versus immunosuppressive adenosine nucleosides. Indeed, CD39 plays a dominant role in the purinergic regulation of inflammation and the immune response because its expression is influenced by genetic and environmental factors. We review the specific role of CD39 in the kinetic regulation of cellular immune responses in the evolution of disease. We focus on the effects of CD39 on T cells and explore potential clinical applications in autoimmunity, chronic infections, and cancer.

    Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Animals; Antigens, CD; Apyrase; Autoimmune Diseases; Autoimmunity; Gene-Environment Interaction; Humans; Immune Tolerance; Infections; Inflammation; Lymphocyte Activation; Neoplasms; T-Lymphocytes

2016
The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy.
    Immunotherapy, 2015, Volume: 7, Issue:2

    Accumulating evidences from animal studies have indicated that both endogenous and exogenous IL-27, an IL-12 family of cytokine, can increase antitumor T-cell activities and inhibit tumor growth. IL-27 can modulate Treg responses, and program effector T cells into a unique T-effector stem cell (TSEC) phenotype, which enhances T-cell survival in the tumor microenvironment. However, animal studies also suggest that IL-27 induces molecular pathways such as IL-10, PD-L1 and CD39, which may downregulate tumor-specific T-cell responses. In this review paper, we will discuss the Yin and Yang aspects of IL-27 in the induction of tumor-specific T-cell responses, and the potential impacts of these functions of IL-27 in the design of cancer immunotherapy.

    Topics: Antigens, CD; Apyrase; B7-H1 Antigen; Humans; Immunotherapy; Interleukin-10; Interleukins; Lymphoid Progenitor Cells; Neoplasms; T-Lymphocytes, Regulatory; Tumor Microenvironment

2015
Targeting cancer-derived adenosine: new therapeutic approaches.
    Cancer discovery, 2014, Volume: 4, Issue:8

    CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes. Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development. In contrast, A(2A) adenosine receptor antagonists have progressed to late-stage clinical trials in Parkinson disease, yet evidence of their role in oncology is limited. This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic.. High concentrations of immunosuppressive adenosine have been reported in cancers, and adenosine is implicated in the growth of tumors. This brief review delineates the current treatment strategies and tumor subtypes that will benefit from targeting adenosinergic pathways, alone or in combination with contemporary approaches to cancer treatment.

    Topics: 5'-Nucleotidase; Adenosine; Animals; Antigens, CD; Apyrase; GPI-Linked Proteins; Humans; Immunosuppressive Agents; Mice; Molecular Targeted Therapy; Neoplasms; Purinergic P1 Receptor Antagonists

2014
ENTPD1/CD39 is a promising therapeutic target in oncology.
    Oncogene, 2013, Apr-04, Volume: 32, Issue:14

    Regulatory T cells (Tregs) are a subpopulation of CD4(+) T cells that are essential for maintaining the homeostasis of the immune system, limiting self-reactivity and excessive immune responses against foreign antigens. In cancer, infiltrated Tregs inhibit the effector lymphocytes and create a favorable environment for the growth of the tumor. Although Tregs mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities. Here, we review the recent literature supporting CD39 as a promising therapeutic target in oncology. In vitro and in vivo experiments involving knockout models and surrogate inhibitors of CD39 provide evidence in support of the anticancer activity of CD39 inhibition and predict a favorable safety profile for CD39 inhibitory compounds. In addition, we report the ongoing development of CD39-blocking monoclonal antibodies as potential anticancer drugs. Indeed, CD39 antagonistic antibodies could represent novel therapeutic tools for selectively inhibiting Treg function without depletion, a major limitation of current Treg-targeting strategies.

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Apyrase; Humans; Neoplasms

2013
Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?
    Trends in molecular medicine, 2012, Volume: 18, Issue:12

    The immune system has important roles in limiting the spread of cancer and shaping the tumor microenvironment. Although the contributions of T helper 17 (Th17) cells (a subtype of CD4(+) T lymphocytes) to autoimmunity and allergy response are well known, their roles in cancer remain ambiguous. Despite adoptive transfer studies indicating that mouse Th17 cells support anticancer immunity, the Th17 cells that naturally infiltrate experimental tumors appear to have a tumor-promoting effect. These contradictory properties can be related to the high degree of plasticity inherent in Th17 cells and their capacity to differentiate into tumoricidal Th1-like cells. Mouse Th17 cells induced by transforming growth factor-β (TGF-β) express CD39 and CD73 ectonucleotidases on their surfaces, which leads to adenosine release and suppression of T cell immunity. Here, we discuss how TGF-β acts as a molecular switch controlling the immunoregulatory properties of Th17 cells.

    Topics: 5'-Nucleotidase; Animals; Antigen-Presenting Cells; Antigens, CD; Apyrase; Cell Differentiation; Immune Tolerance; Immunity, Cellular; Mice; Models, Immunological; Neoplasms; Neovascularization, Pathologic; Th1 Cells; Th17 Cells; Transforming Growth Factor beta

2012
NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.
    BioFactors (Oxford, England), 2007, Volume: 31, Issue:2

    Extracellular nucleotides and nucleosides act as signaling molecules involved in a wide spectrum of biological effects. Their levels are controlled by a complex cell surface-located group of enzymes called ectonucleotidases. There are four major families of ectonucleotidases, nucleoside triphosphate diphosphohydrolases (NTPDases/CD39), ectonucleotide pyrophosphatase/phosphodiesterases (E-NPPs), alkaline phosphatases and ecto-5'-nucleotidase. In the last few years, substantial progress has been made toward the molecular identification of members of the ectonucleotidase families and their enzyme structures and functions. In this review, there is an emphasis on the involvement of NTPDase and 5'-nucleotidase activities in disease processes in several tissues and cell types. Brief background information is given about the general characteristics of these enzymes, followed by a discussion of their roles in thromboregulatory events in diabetes, hypertension, hypercholesterolemia and cancer, as well as in pathological conditions where platelets are less responsive, such as in chronic renal failure. In addition, immunomodulation and cell-cell interactions involving these enzymes are considered, as well as ATP and ADP hydrolysis under different clinical conditions related with alterations in the immune system, such as acute lymphoblastic leukemia (ALL), B-chronic lymphocytic leukemia (B-CLL) and infections associated with human immunodeficiency virus (HIV). Finally, changes in ATP, ADP and AMP hydrolysis induced by inborn errors of metabolism, seizures and epilepsy are discussed in order to highlight the importance of these enzymes in the control of neuronal activity in pathological conditions. Despite advances made toward understanding the molecular structure of ectonucleotidases, much more investigation will be necessary to entirely grasp their role in physiological and pathological conditions.

    Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Atherosclerosis; Blood Coagulation; Blood Platelets; Cell Communication; Demyelinating Diseases; Epilepsy; Humans; Metabolism, Inborn Errors; Myocardial Infarction; Neoplasms; Platelet Activation; Platelet Aggregation; Seizures; Signal Transduction; Tamoxifen; Thrombosis

2007

Other Studies

20 other study(ies) available for apyrase and Neoplasms

ArticleYear
Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:17

    Metabolic interventions via targeting intratumoral dysregulated metabolism pathways have shown promise in reinvigorating antitumor immunity. However, approved small molecule immunomodulators often suffer from ineffective response rates and severe off-target toxicity. ATP occupies a crucial role in energy metabolism of components that form the tumor microenvironment (TME) and influences cancer immunosurveillance. Here, a nanocarrier-assisted immunometabolic therapy strategy that targets the ATP-adenosine axis for metabolic reprogramming of TME is reported. An ecto-enzyme (CD39) antagonist POM1 and AMP-activated protein kinase (AMPK) agonist metformin are both encapsulated into cancer cell-derived exosomes and used as nanocarriers for tumor targeting delivery. This method increases the level of pro-inflammatory extracellular ATP (eATP) while preventing the accumulation of immunosuppressive adenosine and alleviating hypoxia. Elevated eATP triggers the activation of P2X7-NLRP3-inflammasome to drive macrophage pyroptosis, potentiates the maturation and antigen capacity of dendritic cells (DCs) to enhance the cytotoxic function of T cells and natural killer (NK) cells. As a result, synergistic antitumor immune responses are initiated to suppress tumor progress, inhibit tumor distant metastases, provide long-term immune memory that offers protection against tumor recurrence and overcome anti-PD1 resistance. Overall, this study provides an innovative strategy to advance eATP-driven antitumor immunity in cancer therapy.

    Topics: Adaptive Immunity; Adenosine; Adenosine Triphosphate; Apyrase; Biomimetics; Energy Metabolism; Homeostasis; Humans; Neoplasms; Tumor Microenvironment

2022
Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.
    The Journal of clinical investigation, 2022, 07-01, Volume: 132, Issue:13

    Immunosuppressive cells accumulating in the tumor microenvironment constitute a formidable barrier that interferes with current immunotherapeutic approaches. A unifying feature of these tumor-associated immune and vascular endothelial cells appears to be the elevated expression of ectonucleotidase CD39, which in tandem with ecto-5'-nucleotidase CD73, catalyzes the conversion of extracellular ATP into adenosine. We glycoengineered an afucosylated anti-CD39 IgG2c and tested this reagent in mouse melanoma and colorectal tumor models. We identified major biological effects of this approach on cancer growth, associated with depletion of immunosuppressive cells, mediated through enhanced Fcγ receptor-directed (FcγR-directed), antibody-dependent cellular cytotoxicity (ADCC). Furthermore, regulatory/exhausted T cells lost CD39 expression, as a consequence of antibody-mediated trogocytosis. Most strikingly, tumor-associated macrophages and endothelial cells with high CD39 expression were effectively depleted following antibody treatment, thereby blocking angiogenesis. Tumor site-specific cellular modulation and lack of angiogenesis synergized with chemotherapy and anti-PD-L1 immunotherapy in experimental tumor models. We conclude that depleting suppressive cells and targeting tumor vasculature, through administration of afucosylated anti-CD39 antibody and the activation of ADCC, comprises an improved, purinergic system-modulating strategy for cancer therapy.

    Topics: Animals; Antigens, CD; Apyrase; Endothelial Cells; Mice; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment

2022
A tumor-cell biomimetic nanoplatform embedding biological enzymes for enhanced metabolic therapy.
    Chemical communications (Cambridge, England), 2021, Sep-16, Volume: 57, Issue:74

    A tumor cell membrane-camouflaged therapeutic system was fabricated to eliminate tumors by embedding apyrase and glucose oxidase (GOx) into zeolitic imidazolate framework-8 (ZIF-8) nanoparticles for tumor-targeted metabolic therapy. Experimental results demonstrated that these functional nanoparticles could disturb the energy supply of tumor cells by depleting ATP and glucose and efficiently induce tumor cell death.

    Topics: Adenosine Triphosphate; Apyrase; Biomimetic Materials; Cell Death; Glucose; Glucose Oxidase; Humans; Metal-Organic Frameworks; Nanoparticles; Neoplasms

2021
High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    SLAS discovery : advancing life sciences R & D, 2020, Volume: 25, Issue:3

    Production of adenosine in the extracellular tumor microenvironment elicits strong immunosuppression and is associated with tumor progression. Thus, targeting adenosine-generating ectonucleotidases is a potential strategy to stimulate and prolong antitumor immunity. Because the reaction products of ectonucleotidases differ by a single phosphate group, selective detection in an assay format that is compatible with high-throughput screening (HTS) has been elusive. We report the development of biochemical assays capable of measuring the activity of ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1; also known as CD39) and ecto-5'-nucleotidase (CD73). Both assays leverage the Transcreener HTS Assay platform, which facilitates selective immunodetection of nucleotides with homogenous fluorescent readouts, fluorescence polarization or time-resolved fluorescence energy transfer. The Transcreener AMP2 Assay was used to measure CD39 activity, allowing detection of adenosine monophosphate (AMP) production (Z' > 0.6) with subnanomolar amounts of CD39, allowing IC

    Topics: 5'-Nucleotidase; Adenosine Triphosphatases; Antigens, CD; Apyrase; Early Detection of Cancer; High-Throughput Screening Assays; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Tumor Microenvironment

2020
[A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
    Medecine sciences : M/S, 2020, Volume: 36, Issue:2

    Topics: 5'-Nucleotidase; Adaptive Immunity; Adenosine; Antigens, CD; Apyrase; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Signal Transduction

2020
Genetically driven CD39 expression shapes human tumor-infiltrating CD8
    International journal of cancer, 2020, 11-01, Volume: 147, Issue:9

    In our study, we investigated the role of CD39 on tumor-infiltrating CD8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasms; Nivolumab; Polymorphism, Single Nucleotide; Primary Cell Culture; T-Lymphocytes, Cytotoxic

2020
CD39 Identifies the CD4
    Cancer immunology research, 2020, Volume: 8, Issue:10

    The accumulation of tumor-specific CD4

    Topics: Apyrase; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Humans; Neoplasms; T-Lymphocytes

2020
Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39.
    PloS one, 2019, Volume: 14, Issue:10

    The success of immunotherapy treatment in oncology ushered a new modality for treating a wide variety of cancers. However, lack of effect in some patients made it imperative to identify other pathways that are exploited by cancer cells to circumvent immune surveillance, and possibly synergize immune checkpoint treatment in those cases. It has been recently recognized that adenosine levels increase significantly in the tumor microenvironment and that adenosine/adenosine receptors play a powerful role as immunosuppressive and attenuating several effector T cell functions. The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine. Thus, these two enzymes combined are the major source for the bulk of adenosine produced in the microenvironment. They were shown to be validated targets in oncology leading to several clinical trials that include small molecules as well as antibodies, showing positive and encouraging results in the preclinical arena. Towards the development of novel drugs to target these enzymes, we have developed a platform that can be utilized to monitor the activities of both enzymes in vitro (biochemical) as well as in cells (cell based) assays. We have developed very sensitive and homogenous assays that enabled us to monitor the activity of both enzymes and demonstrate selectivity of known inhibitors as well as monoclonal antibodies. This should speed up screening for novel inhibitors that might lead to more effective cancer therapy.

    Topics: 5'-Nucleotidase; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Apyrase; Cell Membrane; GPI-Linked Proteins; Humans; Jurkat Cells; Neoplasm Proteins; Neoplasms; Solubility

2019
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
    Cancer discovery, 2019, Volume: 9, Issue:12

    We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP-P2-mediated proinflammatory responses. Using syngeneic and humanized tumor models, we contrast the potency and mechanism of anti-CD39 mAbs with other agents targeting the adenosinergic pathway. We demonstrate the critical importance of an eATP-P2X7-ASC-NALP3-inflammasome-IL18 pathway in the antitumor activity mediated by CD39 enzyme blockade, rather than simply reducing adenosine as mechanism of action. Efficacy of anti-CD39 activity was underpinned by CD39 and P2X7 coexpression on intratumor myeloid subsets, an early signature of macrophage depletion, and active IL18 release that facilitated the significant expansion of intratumor effector T cells. More importantly, anti-CD39 facilitated infiltration into T cell-poor tumors and rescued anti-PD-1 resistance. Anti-human CD39 enhanced human T-cell proliferation and Th1 cytokine production and suppressed human B-cell lymphoma in the context of autologous Epstein-Barr virus-specific T-cell transfer. SIGNIFICANCE: Overall, these data describe a potent and novel mechanism of action of antibodies that block mouse or human CD39, triggering an eATP-P2X7-inflammasome-IL18 axis that reduces intratumor macrophage number, enhances intratumor T-cell effector function, overcomes anti-PD-1 resistance, and potentially enhances the efficacy of adoptive T-cell transfer.

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Immunological; Apyrase; Cell Line, Tumor; Cell Proliferation; Humans; Inflammasomes; Male; Mice; Neoplasm Transplantation; Neoplasms; Receptors, Purinergic P2X7; Signal Transduction

2019
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Journal for immunotherapy of cancer, 2019, 03-12, Volume: 7, Issue:1

    Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosine. CD39 is expressed by different immune cell populations as well as cancer cells of different tumor types and supports the tumor in escaping immune recognition and destruction. Thus, increasing extracellular ATP and simultaneously reducing adenosine concentrations in the tumor can lead to effective anti-tumor immunity.. We designed locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs) with specificity for human or mouse CD39 that do not need a transfection reagent or delivery system for efficient target knockdown. Knockdown efficacy of ASOs on mRNA and protein level was investigated in cancer cell lines and in primary human T cells. The effect of CD39 knockdown on ATP-degrading activity was evaluated by measuring levels of ATP in tumor cell supernatants and analysis of T cell proliferation in the presence of extracellular ATP. The in vivo effects of CD39-specific ASOs on target expression, anti-tumor immune responses and on tumor growth were analyzed in syngeneic mouse tumor models using multi-color flow cytometry.. CD39-specific ASOs suppressed expression of CD39 mRNA and protein in different murine and human cancer cell lines and in primary human T cells. Degradation of extracellular ATP was strongly reduced by CD39-specific ASOs. Strikingly, CD39 knockdown by ASOs was associated with improved CD8. Targeting of CD39 by ASOs represents a promising state-of-the art therapeutic approach to improve immune responses against tumors.

    Topics: Adenosine; Adenosine Triphosphate; Animals; Antineoplastic Agents, Immunological; Apyrase; Biomarkers, Tumor; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Gene Silencing; Humans; Immunity; Lymphocyte Activation; Mice; Neoplasms; Oligonucleotides, Antisense; T-Lymphocyte Subsets; Xenograft Model Antitumor Assays

2019
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Cancer research, 2018, 09-01, Volume: 78, Issue:17

    Topics: Apyrase; CD8-Positive T-Lymphocytes; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasms

2018
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Cancer research, 2018, 09-01, Volume: 78, Issue:17

    Topics: Apyrase; CD8-Positive T-Lymphocytes; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasms

2018
Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.
    Scientific reports, 2016, Feb-04, Volume: 6

    Tumor cell-derived exosomes (TEX) suppress functions of immune cells. Here, changes in the gene profiles of primary human T lymphocytes exposed in vitro to exosomes were evaluated. CD4(+) Tconv, CD8(+) T or CD4(+) CD39(+) Treg were isolated from normal donors' peripheral blood and co-incubated with TEX or exosomes isolated from supernatants of cultured dendritic cells (DEX). Expression levels of 24-27 immune response-related genes in these T cells were quantified by qRT-PCR. In activated T cells, TEX and DEX up-regulated mRNA expression levels of multiple genes. Multifactorial data analysis of ΔCt values identified T cell activation and the immune cell type, but not exosome source, as factors regulating gene expression by exosomes. Treg were more sensitive to TEX-mediated effects than other T cell subsets. In Treg, TEX-mediated down-regulation of genes regulating the adenosine pathway translated into high expression of CD39 and increased adenosine production. TEX also induced up-regulation of inhibitory genes in CD4(+) Tconv, which translated into a loss of CD69 on their surface and a functional decline. Exosomes are not internalized by T cells, but signals they carry and deliver to cell surface receptors modulate gene expression and functions of human T lymphocytes.

    Topics: Adenosine; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Apyrase; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Culture Media, Conditioned; Down-Regulation; Exosomes; Humans; Lectins, C-Type; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Messenger; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Up-Regulation

2016
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Clinical and experimental immunology, 2014, Volume: 177, Issue:2

    While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare. Therefore, the ability of human T(reg) to produce and utilize ADO for suppression remains unclear. Using mass spectrometry, we measured nucleoside production by subsets of human CD4(+) CD39(+) and CD4(+) CD39(-)CD73(+) T cells or CD19(+) B cells isolated from blood of 30 volunteers and 14 cancer patients. CD39 and CD73 expression was evaluated by flow cytometry, Western blots, confocal microscopy or reverse transcription-polymerase chain reaction (RT-PCR). Circulating CD4(+) CD39(+) T(reg) which hydrolyzed eATP to 5'-AMP contained few intracytoplasmic granules and had low CD73 mRNA levels. Only ∼1% of these T(reg) were CD39(+) CD73(+) . In contrast, CD4(+) CD39(neg) CD73(+) T cells contained numerous CD73(+) granules in the cytoplasm and strongly expressed surface CD73. In vitro-generated T(reg) (Tr1) and most B cells were CD39(+) CD73(+) . All these CD73(+) T cell subsets and B cells hydrolyzed 5'-AMP to ADO. Exosomes isolated from plasma of normal control (NC) or cancer patients carried enzymatically active CD39 and CD73(+) and, when supplied with eATP, hydrolyzed it to ADO. Only CD4(+) CD39(+) T(reg) co-incubated with CD4(+) CD73(+) T cells, B cells or CD39(+) CD73(+) exosomes produced ADO. Thus, contact with membrane-tethered CD73 was sufficient for ADO production by CD4(+) CD39(+) T(reg). In microenvironments containing CD4(+) CD73(+) T cells, B cells or CD39(+) CD73(+) exosomes, CD73 is readily available to CD4(+) CD39(+) CD73(neg) T(reg) for the production of immunosuppressive ADO.

    Topics: 5'-Nucleotidase; Adenosine; Antigens, CD; Apyrase; Cell Line; Cell Membrane; Cells, Cultured; Exosomes; Gene Expression; Humans; Immunophenotyping; Leukocytes, Mononuclear; Lymphocyte Activation; Neoplasms; Phenotype; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2014
Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.
    Cancer research, 2014, Nov-01, Volume: 74, Issue:21

    T cells of the T helper (Th)17 subset offer promise in adoptive T-cell therapy for cancer. However, current protocols for ex vivo programming of Th17 cells, which include TGFβ exposure, increase the expression of CD39 and CD73, two cell surface ATP ectonucleotidases that reduce T-cell effector functions and promote immunosuppression. Here, we report that ATP-mediated suppression of IFNγ production by Th17 cells can be overcome by genetic ablation of CD73 or by using IL1β instead of TGFβ to program Th17 cells ex vivo. Th17 cells cultured in IL1β were also highly polyfunctional, expressing high levels of effector molecules and exhibiting superior short-term control of melanoma in mice, despite reduced stem cell-like properties. TGFβ addition at low doses that did not upregulate CD73 expression but induced stemness properties drastically improved the antitumor effects of IL1β-cultured Th17 cells. Effector properties of IL1β-dependent Th17 cells were likely related to their high glycolytic capacity, since ex vivo programming in pyruvate impaired glycolysis and antitumor effects. Overall, we show that including TGFβ in ex vivo cultures used to program Th17 cells blunts their immunotherapeutic potential and demonstrate how this potential can be more fully realized for adoptive T-cell therapy.

    Topics: 5'-Nucleotidase; Animals; Antigens, CD; Apyrase; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Immune Tolerance; Immunotherapy, Adoptive; Interleukin-1beta; Mice; Neoplasms; Th17 Cells; Transforming Growth Factor beta

2014
Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity.
    European journal of immunology, 2012, Volume: 42, Issue:6

    Intrinsic immunosuppression is a major obstacle for successful cancer therapy. The mechanisms for the induction and regulation of immunosuppression in humans are ill defined. A microenvironmental component that might prevent antitumor immunity is the presence of dying tumor cells, which are abundant following conventional cancer ablation methods such as chemo- or radiotherapy. Shedding of apoptotic debris and/or secretion of factors to the tumor bed or draining lymph nodes thus might have a profound impact on professional phagocytes, such as DCs, and subsequent priming of lymphocytes. Here, we exposed human DCs to supernatants of live, apoptotic, or necrotic human breast cancer cells and cocultured them with autologous T cells. Priming with apoptotic debris prevented DCs from establishing cytotoxicity toward live human tumor cells by inducing a Treg-cell population, defined by coexpression of CD39 and CD69. Immunosuppression via Treg cells was transferable and required the release of sphingosine-1-phosphate (S1P) from apoptotic cells, acting via S1P receptor 4 on DCs to induce IL-27 secretion. We propose that CD69 expression on CD39(+) Treg cells enables them to interact with CD73-expressing CD8(+) T cells to generate adenosine, thereby suppressing cytotoxicity. These findings aid the understanding of how dying tumor cells limit antitumor immunity.

    Topics: Adenosine; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Apoptosis; Apyrase; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Female; Forkhead Transcription Factors; Humans; Interleukins; Lectins, C-Type; Lymphocyte Activation; Neoplasms; Receptors, Lysosphingolipid; T-Lymphocytes, Regulatory

2012
CD39 as a novel marker of in vivo immune activation.
    Blood, 1994, Jun-15, Volume: 83, Issue:12

    Topics: Adenosine Triphosphatases; Antigens, CD; Apyrase; Biomarkers; Humans; Lymphocyte Activation; Neoplasms

1994
Thromboxane production by platelets during tumor cell-induced platelet activation.
    Invasion & metastasis, 1991, Volume: 11, Issue:2

    We have evaluated in a homologous system the mechanisms of platelet activation by cells isolated from fresh human tumor tissues and the role of thromboxane B2 (TxB2) generation in this process. Thirty-eight of the 46 tumor tissues considered showed a high platelet-aggregating activity, with no particular distribution in any specific tumor type. Apyrase caused a nonsignificant reduction in the aggregation response, hirudin did not change it, while iodoacetic acid or p-hydroxymercuriphenylsulfonate, specific cysteine proteinase inhibitors, significantly reduced the platelet-aggregating capacity of these tumor cells. In 9 colon carcinomas and in 8 breast carcinomas the levels of TxB2 produced by platelets after addition of tumor cells were measured: tumor cell-induced platelet aggregation was accompanied by a significant production of the metabolite; indobufen, a cyclooxygenase inhibitor, significantly reduced aggregation and particularly TxB2 production, while the drug had no effect on both parameters if preincubated with tumor cells only. These data suggest that cells isolated from different human tumor tissues activate platelets through the activity of tumor-associated cysteine proteinase(s); platelet aggregation by tumor cells is largely dependent on arachidonic acid metabolism in platelets, while such metabolism in tumor cells does not play a significant role.

    Topics: Adult; Apyrase; Blood Platelets; Dose-Response Relationship, Drug; Hirudins; Humans; Iodoacetates; Iodoacetic Acid; Isoindoles; Neoplasms; Phenylbutyrates; Phenylmercury Compounds; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Radioimmunoassay; Thromboxane B2

1991
Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase.
    Cancer research, 1982, Volume: 42, Issue:11

    Topics: Adenocarcinoma; Animals; Apyrase; Cell Line; Colonic Neoplasms; Glioma; Hirudins; Humans; Kinetics; Lung Neoplasms; Melanoma; Mesothelioma; Mice; Neoplasms; Neoplasms, Experimental; Neuroblastoma; Phospholipases; Phosphoric Monoester Hydrolases; Platelet Aggregation

1982
[Adenosinetriphosphate content and apyrase activity in normal rat liver and rat hepatoma].
    Gan, 1953, Volume: 44, Issue:2-3

    Topics: Adenosine Triphosphate; Animals; Apyrase; Carcinoma, Hepatocellular; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Neoplasms; Phosphoric Monoester Hydrolases; Rats

1953